RGLS - Regulus Therapeutics Inc. Sotuvning sof marjinal rentabelligi

Regulus Therapeutics Inc. - RGLS emitenti grafik logotipi

Regulus Therapeutics (RGLS) hozirda hech qanday daromad keltirmaydi, buning o'rniga yuqori xavfli ishlanmalar va muntazam ravishda yangi aksiyalar chiqarishga tayanadi. Umumiy sof marja ushbu samaradorlik dinamikasini aniq ko'rsatadi, bunda qiymat 0.00 darajasida barqarorlashgan. Elita genetiklar jamoasi miRNA terapiyasini ishlab chiqmoqda, polikistoz buyrak kasalligini davolash bo'yicha 2-fazali sinov natijalari kutilishi esa asosiy o'sish drayveri bo'lib xizmat qilmoqda.

Regulus (RGLS) Sof foyda marjasi: 04.07.2022 - 05.07.2025 davri uchun

RGLS (Regulus Therapeutics): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- bozor qiymati va tahlilchilarning maqsadli prognozi:
- bozor kapitallashuvi statistikasi:
Kompaniyaning fundamental baholanishi:Regulus Therapeutics, Inc. - RGLS
Regulus tayyor mahsulotlari

Regulus Therapeutics (RGLS) polkistoz buyrak kasalligiga qarshi kurashish uchun innovatsion RNK terapiyalarini faol ravishda ishlab chiqmoqda. Klinik sinovlarning yuqori xarajatlari moliyaviy natijalarni operatsion xarajatlarga nisbatan o'ta sezgir qiladi. Ushbu ko'rsatkich barcha biznes xarajatlari chegirib tashlanganidan keyin qolgan daromad foizini belgilaydi. U bir martalik samaradorlikning keskin ortishi va foydaning qisqarishi risklarini aniqlash imkonini beradi. Sof rentabellik grafigini tahlil qilish orqali investor aktivning erkin daromad keltirish borasidagi real qobiliyatini baholaydi.

Regulus Therapeutics (RGLS) raqobatchilari

TEM: Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha marjinallik Qiagen QGEN|IONS (Isis Pharmaceuticals) - Sotuvning sof marjinal rentabelligi|Repligen Inc. - Sof foyda marjasi|Sotuvning sof marjinal rentabelligi RNA|CRSP - Sof marja|GeneDx - Sof foyda bo'yicha sotuv rentabelligi|Sof foyda normasi RARE|Beam Tx - Sotuvning sof marjinal rentabelligi|SRPT - Sotuvning sof marjinal rentabelligi|TWST (Twist Bio) - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof rentabelligi TXG|Sof foyda bo'yicha sotuv rentabelligi NTLA|Stoke Therapeutics Inc (STOK) - Kompaniya sotuv marjasi|Sotuvning sof marjinal rentabelligi BLFS|Sof marja WVE (Wave Life Sciences Corp)|Sof marja Maze Therapeutics MAZE|Sof foyda normasi SION|PRME - Sof marja|Kompaniya sotuv marjasi Taysha TSHA|QURE: Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha sotuv rentabelligi MeiraGTx PLC|RGNX (REGENXBIO Inc) - Sotuvning sof marjinal rentabelligi|solidbio.com (SLDB) - Kompaniya sotuv marjasi|Sof marja Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Sotuvning sof rentabelligi|Benitec Biopharma - Sof foyda bo'yicha sotuv rentabelligi|DSGN: Sotuvning sof rentabelligi|RCKT: Sof foyda bo'yicha sotuv rentabelligi|FDMT - Sotuvning sof marjinal rentabelligi|LXEO: Sotuvning sof marjinal rentabelligi|Korro Bio Inc. - Sof foyda normasi|EDIT (editasmedicine.com) - Sotuvning sof marjinal rentabelligi|Sof marja SLN|Sof marja ProQR Therapeutics NV (PRQR)|Codexis - Sotuvning sof rentabelligi|Sof marja Sangamo SGMO|NAUT: Sotuvning sof rentabelligi|MGX: Sof foyda bo'yicha sotuv rentabelligi|Sof marja Precision BioSciences|GBIO (generationbio.com) - Sof foyda bo'yicha sotuv rentabelligi|Sof marja boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi IMNN (Imunon, Inc.)|Sotuvning sof marjinal rentabelligi PHIO|MBIO - Sof marja|Sotuvning sof marjinal rentabelligi RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Sof marja|Applied DNA - Sotuvning sof marjinal rentabelligi|Sof marja Bluebird Bio|ImmunoPrecise (IPA) - Sof marja|Sof foyda marjasi OMGA (Omega)|Sof marja Singular Genomics Systems|SYRS: Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi TBIO (Telesis Bio Inc.)|Sotuvning sof marjinal rentabelligi TRACON Pharmaceuticals Inc. (TCON)|Sof marja Unity Bio UBX